The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT).
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Celestia S. Higano
Employment - CTI (I)
Leadership - CTI (I)
Stock and Other Ownership Interests - CTI (I)
Honoraria - Genentech
Consulting or Advisory Role - Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen; Myriad Genetics; Orion; Tolmar
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Genentech; Hinova Pharmaceuticals; Menarini; Myriad Genetics; Orion; Pfizer
 
Fred Saad
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst)
 
Kurt Miller
Honoraria - Advanced Accelerator Applications; Amgen; Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sotio; Tolmar
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sotio; Tolmar
Speakers' Bureau - Janssen Oncology
Travel, Accommodations, Expenses - Amgen Astellas BioPharma; Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Tolmar
 
Hsiang-Chun Chen
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Akos Czibere
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Cynthia Healy
Employment - Pfizer; PRA Health Sciences Inc. (I)
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Karim Fizazi
Honoraria - Astellas Pharma; Janssen; Merck; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen; Janssen